Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

January 7, 2029

Study Completion Date

January 7, 2030

Conditions

CD7 PositiveT - Cell Lymphoma

Interventions

DRUG

ASCT+CD7-CART

Intravenous infusion of CD7-CART 3 days after ASCT

Trial Locations (1)

RECRUITING

Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

collaborator

Hebei Taihe Chunyu Biotechnology Co., Ltd

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT07106723 - Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL | Biotech Hunter | Biotech Hunter